Compliance of manufacturers of AST materials and devices with EUCAST guidelines

Similar documents
Compliance of manufacturers of AST materials and devices with EUCAST guidelines

What s new in EUCAST methods?

EUCAST recommended strains for internal quality control

Routine internal quality control as recommended by EUCAST Version 3.1, valid from

European Committee on Antimicrobial Susceptibility Testing

European Committee on Antimicrobial Susceptibility Testing

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing

AMR Industry Alliance Antibiotic Discharge Targets

a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.

Antimicrobial Susceptibility Testing: Advanced Course

21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review

SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* ...

2015 Antibiotic Susceptibility Report

2016 Antibiotic Susceptibility Report

EUCAST-and CLSI potency NEO-SENSITABS

British Society for Antimicrobial Chemotherapy

National Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults

Streptococcus pneumoniae. Oxacillin 1 µg as screen for beta-lactam resistance

British Society for Antimicrobial Chemotherapy

THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS

January 2014 Vol. 34 No. 1

Performance Information. Vet use only

56 Clinical and Laboratory Standards Institute. All rights reserved.

January 2014 Vol. 34 No. 1

BSAC standardized disc susceptibility testing method (version 8)

Antimicrobial Susceptibility Testing: The Basics

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting

Background and Plan of Analysis

جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی

Antimicrobial susceptibility

Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?

EAGAR Importance Rating and Summary of Antibiotic Uses in Humans in Australia

What is new in 2011: Methods and breakpoints in relation to subcommittees and expert groups. by author. Gunnar Kahlmeter, Derek Brown

Concise Antibiogram Toolkit Background

- the details, where possible, of the antibiotic products these companies supply or have supplied.

Introduction. Antimicrobial Usage ESPAUR 2014 Previous data validation Quality Premiums Draft tool CDDFT Experience.

Penicillins - EUCAST clinical MIC breakpoints (version 1.3)

Intrinsic, implied and default resistance

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

MicroScan Microbiology Systems MORE CHOICES MORE ANSWERS. MicroScan GRAM NEGATIVE AND GRAM POSITIVE PANELS

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Antibiotics.

INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER

Brief reports. Heat stability of the antimicrobial activity of sixty-two antibacterial agents

CONTAGIOUS COMMENTS Department of Epidemiology

Interpreting Microbiology reports for better Clinical Decisions Interpreting Antibiogrammes

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016

Understanding the Hospital Antibiogram

EUCAST 2016/17 and what to do when there are no breakpoints and if the UK should exit EU

1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient

Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018

Perichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV

Antibiotic Abyss. Discussion Points. MRSA Treatment Guidelines

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

Available online at ISSN No:

Antimicrobial Susceptibility Patterns

2 New products for 2014

GENERAL NOTES: 2016 site of infection type of organism location of the patient

CONTAGIOUS COMMENTS Department of Epidemiology

A Multi-Laboratory Study of the BIOMIC Automated Well Reading Instrument versus

MASTDISCS AST. Leading the field with a complete solution for AST and Identification disc testing. Comprehensive range. Premium quality products

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

CAP Laboratory Improvement Programs. Performance Accuracy of Antibacterial and Antifungal Susceptibility Test Methods

Antimicrobial susceptibility testing challenges. Linda Joyce St Vincent s Hospital Melbourne

Childrens Hospital Antibiogram for 2012 (Based on data from 2011)

BactiReg3 Event Notes Module Page(s) 4-9 (TUL) Page 1 of 21

EUCAST expert rules in antimicrobial susceptibility testing

Measuring Antibiotic Use in NHSN

REVOLUTIONARY. MMinimum. BBiofilm EEradication Concentration. inimizing WE HAVE FOUND THE ANSWER.

Recommendations to take it forward!

Version 7, January 2008

Liofilchem. ID-AST systems

Version 6, January 2007

Version 13 January 2014

This document is protected by international copyright laws.

Should we test Clostridium difficile for antimicrobial resistance? by author

Aberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015

Advanced Practice Education Associates. Antibiotics

TABLE OF CONTENTS. Urine - Gram Positive Susceptibility Reporting 1 Staphylococcus species, MRSA...11

Approach to pediatric Antibiotics

2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services

Antibiotic Updates: Part II

ESCMID Online Lecture Library. by author

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018

Quality ID #66: Appropriate Testing for Children with Pharyngitis National Quality Strategy Domain: Efficiency and Cost Reduction

Antimicrobial Resistance Surveillance from sentinel public hospitals, South Africa, 2013

Consumption of antibiotics in hospitals. Antimicrobial stewardship.

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority

Version 10.1 April 2011

Medicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck!

دکتر فرينبز راشذ مرنذی متخصص آسيب شنبسی تشريحی و ببلينی عضو هيئت علمی آزمبيشگبه مرجع سالمت

Version 9.1 March 2010

Version 8 January 2009

Non-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland,

Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory

There are two international organisations that set up guidelines and interpretive breakpoints for bacteriology and susceptibility

Canadian Nosocomial Infection Surveillance Program 2018 SURVEILLANCE FOR HEALTHCARE ACQUIRED CEREBROSPINAL FLUID SHUNT ASSOCIATED INFECTIONS

Product Catalogue 2017 Clinical and Industrial Microbiology

Transcription:

Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The tables will be updated when manufacturers report changes (contact erika.matuschek@ltkronoberg.se). The accuracy of data in these tables is not verified by EUCAST and the inclusion of any materials or devices does not indicate endorsement by EUCAST. Last updated 29 January 2014

EUCAST disk diffusion method Manufacturer Disks available MH-F plates available Abtek All No BD All except: Ceftibuten 30µg Bio-Rad All biomérieux No disks marketed I2a All No Liofilchem All MAST Group All No but supply β-nad supplement Thermo Fisher Scientific (Oxoid) All Rosco All (Neo-Sensitabs) No No

Automated systems for reading antimicrobial susceptibility testing plates Manufacturer System EUCAST breakpoints EUCAST Expert Rules EUCAST terminology S R> - IE Bio-Rad OSIRIS/ADAGIO. There are additional rules but EUCAST rules have priority. Giles Scientific BIOMIC V3. No exceptions I2a SIRSCAN: 2000 2000 automatic Micro. There are additional rules but none should be contrary to EUCAST rules.

Gradient tests: Etest Manufacturer Agents in EUCAST tables but not available Agents validated for MH-F biomérieux Amoxicillin-clavulanic acid (fixed 2 mg/l clavulanic acid)*, ** Ampicillin-sulbactam (fixed 4 mg/l sulbactam)*, ** Cefadroxil Cefalexin Cefazolin Ceftibuten Ticarcillin Ampicillin Benzylpenicillin Cefaclor Cefotaxime Ceftriaxone Cefuroxime Doripenem Ertapenem Imipenem Meropenem Chloramphenicol Clindamycin Erythromycin Levofloxacin Moxifloxacin Ofloxacin Tetracycline Trimethoprim-sulfamethoxazole (not for H. influenzae and M. catarrhalis) Vancomycin *Gradient tests with the agent:inhibitor in a 2:1 ratio are not acceptable using EUCAST methods and breakpoints ** Expected during 2014

Gradient tests: MIC Test Strip Manufacturer Agents in EUCAST tables but not available Agents validated for MH-F Liofilchem Cefadroxil Cefalexin Cefazolin Ceftibuten Telithromycin Ticarcillin Amoxicillin Amoxicillin-clavulanic acid (fixed 2 mg/l clavulanic acid)* Ampicillin Ampicillin-sulbactam (fixed 4 mg/l sulbactam)* Azithromycin Benzylpenicillin Cefaclor Cefepime Cefixime Cefotaxime Cefpodoxime Ceftaroline Ceftriaxone Cefuroxime Cephalothin Chloramphenicol Ciprofloxacin Clarithromycin Clindamycin Doripenem Doxycycline Ertapenem Erythromycin Imipenem Levofloxacin Linezolid Meropenem Minocycline Moxifloxacin Ofloxacin Rifampicin Teicoplanin Tetracycline Trimethoprim-sulfamethoxazole Vancomycin *Gradient tests with the agent:inhibitor in a 2:1 ratio are not acceptable using EUCAST methods and breakpoints

Gradient tests: M.I.C.Evaluator Manufacturer Agents in EUCAST tables but not available Agents validated for MH-F Thermo Fisher Scientific (Oxoid) Amoxicillin-clavulanic acid (fixed 2 mg/l clavulanic acid)* Ampicillin-sulbactam (fixed 4 mg/l sulbactam)* Azithromycin Aztreonam Cefaclor Cefadroxil Cefalexin Cefazolin Cefepime Cefixime Cefoxitin Cefpodoxime Ceftibuten Cefuroxime Chloramphenicol Clarithromycin Colistin Doripenem Doxycycline Ertapenem Fosfomycin Fusidic acid Mecillinam Minocycline Moxifloxacin Mupirocin Nalidixic acid Netilmicin Nitrofurantoin Norfloxacin Ofloxacin Piperacillin Piperacillin-tazobactam Quinupristin-dalfopristin Rifampicin Spectinomycin Streptomycin Telavancin Telithromycin Ticarcillin Ticarcillin-clavulanate Tobramycin Trimethoprim Trimethoprim-sulfamethoxazole Amoxicillin Ampicillin Benzylpenicillin Oxacillin Cefotaxime Ceftazidime Ceftaroline Levofloxacin Amikacin Teicoplanin Vancomycin Erythromycin Tetracycline Tigecycline Linezolid *Gradient tests with the agent:inhibitor in a 2:1 ratio are not acceptable using EUCAST methods and breakpoints

Phoenix/EpiCenter automated system (BD) EUCAST terminology In computer database S R > No (R ) - IE S EUCAST Expert Rules EUCAST organism groups with no test in the system Agents in EUCAST tables but not available in the system Agents available but EUCAST breakpoints not in the system In reports R > ( converted to R >) - (MICs reported for agents with no EUCAST breakpoints) IE (MICs reported for agents with no EUCAST breakpoints) All rules incorporated. There are additional rules but EUCAST rules have priority. H. influenzae M. catarrhalis N. meningitidis N. gonorrhoeae Ampicillin-sulbactam (fixed 4 mg/l sulbactam)* Gram-negative anaerobes Gram-positive anaerobes Rifampicin (Staphylococcus spp. cannot be reported susceptible) Trimethoprim (Enterococcus spp. cannot be reported susceptible) Trimethoprim-sulfamethoxazole (Enterococcus spp. cannot be reported susceptible) *Tests with the agent:inhibitor in a 2:1 ratio are not acceptable using EUCAST methods and breakpoints

Microscan automated system (Siemens Healthcare Diagnostics) EUCAST terminology In computer database S R > - No IE No S EUCAST Expert Rules EUCAST organism groups with no test in the system Agents in EUCAST tables but not available in the system Agents available but EUCAST breakpoints not in the system In reports R > - Most - do not have interpretations reported IE No Some exceptions in current rules will be corrected in new software release Jan-March 2013. All rules can be customised by user. H. influenzae M. catarrhalis Strep A, C and G Chloramphenicol Fusidic acid Rifampicin Trimethoprim Doxycycline N. meningitidis N. gonorrhoeae S. pneumoniae Gram-negative anaerobes Gram-positive anaerobes Viridans streptococci (except S. bovis) Ampicillin-sulbactam (fixed 4 mg/l sulbactam)* Amoxicillin-clavulanic acid (fixed 2 mg/l clavulanic acid)* All agents for anaerobes Telithromycin Tigecycline (Gram-positive organisms) *Tests with the agent:inhibitor in a 2:1 ratio are not acceptable using EUCAST methods and breakpoints

Vitek 2 automated system (biomérieux) S In computer database R > No. Will be in V2S 7.01 s/w, due Q1 2014. - No. Will be in V2S 7.01 s/w, due in Q1 2014. EUCAST terminology IE No. Will be in V2S 7.01 s/w, due in Q1 2014. S In reports R > No. Will be in V2S 7.01 s/w, due Q1 2014. - Reported blank. Will be in V2S 7.01 s/w, due Q1 2014. IE Reported blank. Will be in V2S 7.01 s/w, due Q1 2014. EUCAST Expert Rules EUCAST organism groups with no test in the system Agents in EUCAST tables but not available in the system Agents available but EUCAST breakpoints not in the system All applicable rules dealing with intrinsic resistance, therapeutic interpretation and deduction are in software version V2S 5.03 (2011), 5.04(2011), & 6.01 (2012). There are additional rules but none should be contrary to EUCAST rules in these software version. H. influenzae M. catarrhalis N. meningitidis N. Gonorrhoeae Azithromycin Amoxicillin-clavulanic acid (fixed 2 mg/l clavulanic acid )* in development Ampicillin-sulbactam (fixed 4 mg/l sulbactam) * will be available for Gram negative AST in V2S 7.01 s/w, due in Q1 2014) Cefadroxil Ceftibuten Rifampicin (Strep spp.) Will be in V2S 7.01 s/w, due in Q1 2014 Trimethoprim (Enterococcus spp. & Gr. B strep) Vancomycin (CNS) Will be in V2S 7.01 s/w due in Q1 2014 Linezolid (S. pneumoniae) Will be in V2S 7.01 s/w due in Q1 2014 Gentamicin (Enterococcus spp.) in development Mupirocin (S. aureus) Will be in V2S 7.01 s/w due in Q1 2014 Gram-negative anaerobes Gram-positive anaerobes Ceftaroline Cefepime (S. pneumoniae) Cefpodoxime (S. pneumoniae) Cefuroxime (S. pneumoniae) Teicoplanin (S. pneumoniae) Doxycycline (S. pneumoniae) Minocycline (S. pneumoniae) Netilmicin (Staphylococcus spp.) Tri-sulfa (Enterococcus spp.) Ofloxacin (S. pneumoniae ) Steptomycin (Enterococcus spp.) Antifungals All agents with P. multocida *Tests with the agent:inhibitor in a 2:1 ratio are not acceptable using EUCAST methods and breakpoints